[Folate against hyperhomocysteinemia. A new approach for the prevention and therapy of alcoholism-associated disorders?].
There is growing evidence that chronic alcoholism is associated with a derangement in the sulfur amino acid metabolism. Excitatory aminoacids such as glutamate, aspartate, and homocysteine have been shown to be increased in patients with chronic alcoholism who underwent alcohol withdrawal. Furthermore, sustained hyperhomocysteinemia occurred in chronic alcoholics with active drinking pattern. Excitotoxicity can be induced by increased hormocysteine levels via rebound activation of NMDA receptor-mediated glutamatergic neurotransmission upon the removal of ethanol-evoked inhibition. Therefore, hyperhomocysteinemia may be responsible for the higher incidence of complications during alcohol withdrawal (e.g.stroke,convulsions). In addition, an association between brain atrophy and increased levels of homocysteine in chronic alcoholism was shown. This may have important implications for the pathogenesis of brain atrophy in alcoholics. Taking into account that high plasma homocysteine levels are helpful in the prediction of alcohol withdrawal seizures, early anti-convulsive therapy could prevent this severe complication. Supplementation of folate, a cofactor of the homocysteine metabolism, lowers raised homocysteine levels and therefore could be established as a new therapeutic strategy in alcohol withdrawal treatment. The results of various studies highlight the need for further research to prove whether alcoholics benefit from a reduced homocysteine level with respect to both, alcohol-related disorders and alcohol withdrawal symptoms.
Bleich
S
S
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Friedrich-Alexander- Universität Erlangen-Nürnberg, Erlangen. stefan.bleich@psych.imed.uni-erlangen.de
Löffelholz
K
K
Kornhuber
J
J
D020270:Alcohol Withdrawal Seizures / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D019973:Alcohol-Related Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D000437:Alcoholism / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D005492:Folic Acid / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000188:drug therapy* / Q000517:prevention & control; D010346:Patient Care Management / Q000379:methods
D006397:Hematinics; D005492:Folic Acid